UroGen Pharma Ltd. — Director's Dealing 2020

Jan 28, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-01-26

Reporting Person: Schoenberg Mark (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-26	Ordinary Shares	M	833	—	Acquired	9499	Direct
2020-01-27	Ordinary Shares	S	322	$29.15	Disposed	9177	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-26	Restricted Stock Units (RSUs)	$	M	833	Disposed		Ordinary Shares (833)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

F2: The transaction reported herein was matchable under Section 16(b) of the Securities and Exchange Act of 1934, to the extent of 322 shares, with the reporting person's purchase of 1,960 ordinary shares of the Issuer at a price of $28.17 per share on November 19, 2019. The reporting person has paid to the Issuer $315.56, representing the full amount of the profit realized in connection with the short-swing transaction.

F3: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F4: The reporting person was granted 2,500 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter.